| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 04/06/2006 | WO2006035900A1 Coenzyme q10-containing emulsified composition |
| 04/06/2006 | WO2006035797A1 Nonanimal-origin soft capsule coating and soft capsule having the same |
| 04/06/2006 | WO2006035725A1 Isocyclomaltooligosaccharide, isocyclomaltooligosaccharide synthase, process for producing them and use thereof |
| 04/06/2006 | WO2006035717A1 Antitumor composition |
| 04/06/2006 | WO2006034849A1 Antitumoral pharmaceutical compositions comprising a spisulosine and a cyclodextrin |
| 04/06/2006 | WO2005123138A9 Pharmaceutical pellet compositions for controlled release |
| 04/06/2006 | WO2005120578A9 Biodegradable drug-polymer delivery system |
| 04/06/2006 | WO2005113592A3 Interferon-alpha polypeptides and conjugates |
| 04/06/2006 | WO2005110360A3 Compositions for injection |
| 04/06/2006 | WO2005041937A3 Controlled release sterile injectable aripiprazole formulation and method |
| 04/06/2006 | WO2005018572A3 Improved antibodies having altered effector function and methods for making the same |
| 04/06/2006 | WO2005007798A3 Hydroxypropyl methacrylamide polymers and copolymers comprising reactive thiazoline-2-thione |
| 04/06/2006 | WO2004076621A3 Compositions of nucleic acids for treating and detecting influenza virus |
| 04/06/2006 | US20060074048 Mixed esters of hyaluronic acid with retinoic and butyric acids |
| 04/06/2006 | US20060074027 Microcapsules of luteinizing hormone releasing hormone agonists; glycolic acid-lactic acid copolymers; for treating prostate cancer, prostatomegaly, endometriosis, hysteromyoma, metrofibroma, precocious puberty, dymenorrhea or breast cancer, or inhibiting conception |
| 04/06/2006 | US20060074025 Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability |
| 04/06/2006 | US20060074013 Insulin, insulin-related peptide, and sensitizer; side effect reduction |
| 04/06/2006 | US20060074011 pH above 5.5 may be delivered to a subject with reduced pain |
| 04/06/2006 | US20060074009 Natriuretic compounds, conjugates, and uses thereof |
| 04/06/2006 | US20060074008 monoclonal antibody conjugated with peptide drug such as dolastatin derivative |
| 04/06/2006 | US20060073333 Dispersing a matrix of nanostructured liquid phase or a dehydrated variant and a nanostructured liquid crystalline phase or a dehydrated variant in nonlamellar material; cooling or evaporating a volatile solvent |
| 04/06/2006 | US20060073189 Chewing gums, lozenges, candies, tablets, liquids, and sprays for efficient delivery of medications and dietary supplements |
| 04/06/2006 | US20060073188 Fast-dissolving isotropic expanded microporous composition or structure for pharmaceutical, veterinary, dietetic, food or cosmetic use and method for obtaining same |
| 04/06/2006 | US20060073187 Use of arachidonic acid for normalization of infradian rhythm |
| 04/06/2006 | US20060073186 Nutritional compositions |
| 04/06/2006 | US20060073176 Water-soluble composition containing coenzyme q10 |
| 04/06/2006 | US20060073175 Methods and formulations for delivery of pharmacologically active agents |
| 04/06/2006 | US20060073163 Anti-sepsis conjugate vaccine |
| 04/06/2006 | US20060073150 monoclonal antibodies or antigen binding fragments that specifically to six transmembrane epithelial antigens of the prostate (STEAP-1), used for medical diagnosis, prognosis, prophylaxis and/or therapy for cancers |
| 04/06/2006 | US20060073146 Uses of agonists and antagonists to modulate activity of TNF-related molecules |
| 04/06/2006 | US20060073143 Treatment with anti-ErbB2 antibodies and anti-hormonal compounds |
| 04/06/2006 | US20060073140 Dual-specificity antibody having specificity for both an activated erbB2 receptor and erbB1 dimers, without significant affinity for monomeric EGFr that is not activate; specificity of the antibodies is due to their recognition and binding of activation epitopes; diagnosis, imaging and for treating tumor |
| 04/06/2006 | US20060073114 Compounds and methods to inhibit or augment an inflammatory response |
| 04/06/2006 | US20060073105 Novel dry powder inhalation system for transpulmonary administration |
| 04/06/2006 | US20060073103 Controlled Dosage Aerosols With Lecithin As Surface-Active Agent |
| 04/06/2006 | US20060073100 Detection and therapy of vulnerable plaque with fluorescent and/or radiolabeled compositions |
| 04/06/2006 | CA2581487A1 Isocyclomaltooligosaccharide (s), isocyclomaltooligosaccharide-forming enzyme, their preparation and uses |
| 04/06/2006 | CA2580953A1 Antitumor composition |
| 04/06/2006 | CA2579297A1 Semi-solid delivery vehicle and pharmaceutical compositions |
| 04/05/2006 | EP1642904A1 Protein achieving improved blocking efficiency |
| 04/05/2006 | EP1642596A2 Treatment of autoimmune diseases with antagonists which bind to B cell surface markers |
| 04/05/2006 | EP1642595A1 Hydrogel composition comprising crosslinked polyethylene oxide and methods for production |
| 04/05/2006 | EP1642584A1 External preparation for improving coital function |
| 04/05/2006 | EP1642582A1 Low dose entecavir formulation and use |
| 04/05/2006 | EP1642579A1 Phentanyl-containing adhesive patch for application to oral-cavity mucosa |
| 04/05/2006 | EP1642578A2 Fentanyl composition for nasal administration |
| 04/05/2006 | EP1642571A2 Method for preparing submicron particle suspensions |
| 04/05/2006 | EP1642561A1 Cosmetic composition containing sulfonated polymers with sulfone groups |
| 04/05/2006 | EP1642132A2 Glycoconjugates and their use as potential vaccines against infection by shigella flexneri |
| 04/05/2006 | EP1641490A2 Modified calcium phosphate excipient |
| 04/05/2006 | EP1641487A1 Liquid composition of factor vii polypeptides |
| 04/05/2006 | EP1641486A1 Stable, aqueous solution of human erythropoietin, not containing serum albumin |
| 04/05/2006 | EP1641481A2 Formation of novel erythropoietin conjugates using transglutaminase |
| 04/05/2006 | EP1641459A1 Use of osmolytes obtained from extremophilic bacteria for producing medicaments for the external treatment of neurodermatitis |
| 04/05/2006 | EP1641437A1 The solid dispersion of tacrolimus |
| 04/05/2006 | EP1641434A1 Pharmaceutical formulations for intranasal administration of protein comprising chitosan or a derivative thereof |
| 04/05/2006 | EP1641424A2 Programmed immune responses using a vaccination node |
| 04/05/2006 | EP1524975B1 Improved transdermal delivery system for the administration of rotigotine |
| 04/05/2006 | EP1465636A4 Compositions and methods for enhancing corticosteriod delivery |
| 04/05/2006 | EP1450822A4 Polymeric thiol-linked prodrugs |
| 04/05/2006 | EP1383522B1 A medicament or a dressing containing a metal such as silver, gold, platinum or palladium as an antimicrobial agent and their use in the treatment of inflammatory skin conditions |
| 04/05/2006 | EP1370544B1 Nitric oxide donors based on metallic centres |
| 04/05/2006 | EP1310517B1 Lactic acid polymer and process for producing the same |
| 04/05/2006 | EP1294359B1 Process for preparing and harvesting crystalline particles |
| 04/05/2006 | EP1289504B1 Neurotoxin implant |
| 04/05/2006 | EP1210104B1 Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
| 04/05/2006 | EP1107783B1 Method for inducing a cell-mediated immune response and parenteral vaccine formulations therefor |
| 04/05/2006 | EP1085901B1 Transdermal use of secretin for the treatment of autism |
| 04/05/2006 | EP0965339B1 Tabletted nateglinide preparation |
| 04/05/2006 | EP0862453B1 Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis |
| 04/05/2006 | EP0772773B1 Src SH3 BINDING PEPTIDES AND METHODS OF ISOLATING AND USING SAME |
| 04/05/2006 | CN1756768A Trimeric polypeptide construct to induce an enduring t cell response |
| 04/05/2006 | CN1756571A Tissue reactive compounds and compositions and uses thereof |
| 04/05/2006 | CN1756559A Stabilized aqueous compositions comprising tissue factor pathway inhibitor (TFPI) or tissue factor pathway inhibitor variant |
| 04/05/2006 | CN1756557A Sincalide formulations |
| 04/05/2006 | CN1754889A Pegylated interferon alpha-1b |
| 04/05/2006 | CN1754575A Oral insulin protecting agent |
| 04/05/2006 | CN1754536A Solution formulations of sirolimus and its analogs for cad treatment |
| 04/05/2006 | CN1754532A Plaster matrix containing emulsifier and its preparation method |
| 04/05/2006 | CN1249229C Soluble T cell receptor |
| 04/05/2006 | CN1248738C Testosterone ester formulation for human use |
| 04/05/2006 | CN1248691C Controlled release peroral compositions of levosimendan |
| 04/05/2006 | CN1248689C Injectable bupernorphine microparticle compositions and their use |
| 04/05/2006 | CN1248688C Targeted freeze dried nanometer powder injection of hydroxycamptothecine bean phospholipid and its preparation method |
| 04/05/2006 | CN1248685C Analgesic/anti-inflammatory patches for topical use |
| 04/05/2006 | CN1248681C Solid orally-dispersible pharmaceutical formulation |
| 04/05/2006 | CN1248680C Injectable composition of paclitaxel |
| 04/05/2006 | CN1248679C Water soluble microflake through air gap and process thereof |
| 04/05/2006 | CA2479539A1 Recombinant adenylate cyclase / hiv-tat protein and therapeutic and diagnostic uses thereof |
| 04/04/2006 | USRE39055 Hepatoselective pharmaceutical actives |
| 04/04/2006 | US7022832 Wherein secondary structure disintegrates upon attachment of the oligonucleotide to a target nucleic acid; anticarcenogenic agents, treatment of Ewing's sarcoma |
| 04/04/2006 | US7022791 crosslinked copolymers of acryloyldimethyltaurine |
| 04/04/2006 | US7022740 Lubricious ophthalmic solutions |
| 04/04/2006 | US7022727 From amorphous 6-[(2,2-diphenylethyl)amino]-9-(N-ethyl- beta -D-ribofuranosyluronamide)-N-(2-{N'-[1-(2-pyridyl)-4-piperidyl]ureido}ethyl)-9H-purine-2-carboxamide; agonising an adenosine receptor; easily purified, stable, easily micronized for inhalants |
| 04/04/2006 | US7022712 Acidification of drugs such as carbendazim, by mixing with buffers improving water solubility; anticarcinogenic agents |
| 04/04/2006 | US7022692 comprises water soluble binder and sweetener; for treating central nervous system disorders such as psychotic disease conditions including schizophrenia |
| 04/04/2006 | US7022678 Pregabalin lactose conjugates |
| 04/04/2006 | US7022673 Generation of biocompatible active macromolecules with amplified half-life; obtain macromolecule, couple to polymer, recover macromolecule |
| 04/04/2006 | US7022672 Formulation, solubilization, purification, and refolding of tissue factor pathway inhibitor |
| 04/04/2006 | US7022661 for use as emulsifiers, hair conditioners and fabric softeners; pollution control |